Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;30(2):84-91.
doi: 10.1097/CCO.0000000000000431.

Treatment of ALK-positive nonsmall cell lung cancer: recent advances

Alesha A Thai  1 , Benjamin J Solomon  1   2
Affiliations
Review

Treatment of ALK-positive nonsmall cell lung cancer: recent advances

Alesha A Thai et al. Curr Opin Oncol. 2018 Mar.

Abstract

Purpose of review: The review will highlight recent advances in development of ALK-TKIs and management of patients with ALK-positive nonsmall cell lung cancer.

Recent findings: There has been rapid progress in the use of targeted therapies for ALK-positive NSCLC. Since the discovery, development and approval of crizotinib in 2011, three second-generation ALK-TKIs, ceritinib, alectinib and brigatinib have been approved by the FDA. A range of newer generation ALK inhibitors with improved potency against ALK and against mutations that confer resistance to crizotinib are in clinical development.

Summary: Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical trials with other ALK inhibitors. We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms.

PubMed Disclaimer

MeSH terms

Substances